Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. M3, Inc.
  6. News
  7. Summary
    2413   JP3435750009

M3, INC.

(2413)
  Report
Delayed Japan Exchange  -  01:00 2022-12-01 am EST
4192.00 JPY   -0.31%
11/15Segmed, Inc. announced that it has received $5.2 million in funding from Nina Capital SGEIC, S.A, iGan Partners, M3, Inc., Mighty Capital, Expeditions Fund, Alchemist Accelerator, LLC
CI
11/02M3's Fiscal H1 Attributable Profit Plunges 41% on High-base Effect
MT
11/02M3 : Presentation Material
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

M3 : Acquires MirVracha LCC in Russia ~ Launching Full-Scale Development of Physician Platform Business in Russia ~

02/02/2022 | 01:39am EST

FOR IMMEDIATE RELEASE: 2022/2/2

M3 Acquires MirVracha LCC in Russia

~ Launching Full-Scale Development of Physician Platform Business in Russia ~

M3, Inc. (Headquarters: Tokyo, Japan; CEO: Itaru Tanimura; URL: https://corporate.m3.com/; "M3"

below) has announced the acquisition of MirVracha LCC (Headquarters: Moscow, Russia; CEO: Shotaro Yamamoto; "MirVracha" below), a website provider for healthcare professionals in Russia.

M3 operates m3.com, a specialized web portal for medical professionals that delivers healthcare related information to its 300,000+ physician members in Japan. Presence outside of Japan includes the U.S., U.K., France, China, Korea and India, with aggressive business expansion overseas that has amassed over 6 million physicians as members across its global platforms. This allows provision of services including marketing support, marketing research, and job placement support that leverage the platform's powerful value as a media channel.

MirVracha operates the medical professional website "МирВрача" with over 400,000 medical professional members, equivalent to roughly 60% of all physicians in Russia, and mainly provides marketing support services for pharmaceutical companies. Since its founding by Shotaro Yamamoto in 2011, MirVracha has focused on building a quality network of healthcare professionals as well as improving content creation capabilities, and is now utilized by major Russian pharmaceutical companies to provide drug and disease information. In 2012, M3 entered into a capital and business alliance that includes the licensing of the MR-kun service, and have since developed a strong relationship with MirVracha through provision of support and know-how surrounding business launches and operations.

M3 has completed the acquisition of MirVracha as a subsidiary, and will leverage its experience and know-how gained through its overseas business development in the United States, Europe, Asia, and other regions. M3 will move forward with the full-scale development of services related to its physician platform in Russia by combining the high-quality network of physicians, medical institutions, and pharmaceutical companies that MirVracha has cultivated in Russia, with M3's expertise in operating websites and various services for healthcare professionals.

  • Website capture of MirVracha
  • Company overview
    Limited liability company "MirVracha" Established: September, 2011 Headquarters: Moscow, Russia URL: https://mirvracha.ru/
    Representative Director and President: Shotaro Yamamoto
    Business: Provision and operation of website for physicians

Disclaimer

M3 Inc. published this content on 02 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 February 2022 06:38:06 UTC.


ę Publicnow 2022
All news about M3, INC.
11/15Segmed, Inc. announced that it has received $5.2 million in funding from Nina Capital S..
CI
11/02M3's Fiscal H1 Attributable Profit Plunges 41% on High-base Effect
MT
11/02M3 : Presentation Material
PU
11/02M3 : Summary of Consolidated Financial Results
PU
10/30M3 : White Jack Project Phase 4, 'EBHS Life' launched; New health indicator ~ Predicting r..
PU
10/26Nikkei 225 Up 0.7% on Earnings, Central Bank Outlooks
MT
10/24Segmed, Inc. announced a financing transaction
CI
10/18Nikkei 225 Up 1.4% on Wall Street Cues
MT
10/18Japanese stocks end higher as Wall Street, U.S. futures rally
RE
10/18Japanese stocks rebound as U.S. futures rise
RE
More news
Financials
Sales 2023 240 B 1 721 M 1 721 M
Net income 2023 53 212 M 382 M 382 M
Net cash 2023 154 B 1 107 M 1 107 M
P/E ratio 2023 53,6x
Yield 2023 0,42%
Capitalization 2 855 B 20 486 M 20 486 M
EV / Sales 2023 11,3x
EV / Sales 2024 10,0x
Nbr of Employees 9 384
Free-Float 60,2%
Chart M3, INC.
Duration : Period :
M3, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends M3, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 4 205,00 JPY
Average target price 5 093,85 JPY
Spread / Average Target 21,1%
EPS Revisions
Managers and Directors
Itaru Tanimura President & Representative Director
Ryoko Toyama Independent Outside Director
Masako Ii Independent Outside Director
Mayuka Yamazaki Independent Outside Director
Kenichiro Yoshida Outside Director
Sector and Competitors
1st jan.Capi. (M$)
M3, INC.-27.41%20 486
ALPHABET INC.-30.28%1 309 913
VISA, INC.0.13%447 386
TENCENT HOLDINGS LIMITED-37.13%346 578
MASTERCARD, INC.-0.81%342 664
META PLATFORMS, INC.-64.89%313 148